New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management

About this update from Photocure Asa

[{"type":"text","content":"OSLO, Norway , Nov. 19, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study "Hexaminolevulinate-enhanced photodynamic diagnosis in the management of non-muscle-invasive bladder cancer (NMIBC): The influence of differing European health care payment systems on the potential financial impact of adoption" in the Journal of Medical Economics this week. The research objective was to compare the economic implications of blue light cystoscopy (BLC®) adoption in line with national guideline recommendations in four European markets.The analysis further explores the impact of the different health care payment systems on the budgetary impact of BLC adoption by a hospital.","length":746,"tagName":"p"},{"type":"text","content":"Methods: A previously published budget impact model was adapted to allow for the exploration of costs across four different payment environments: Denmark, France, Italy and Finland. Using the same set of clinical assumptions around disease risk profiles, recurrence rates and usage of PDD, but applying local treatment guidelines and country-specific costs per country, the net budget impact per patient with NMIBC was estimated for each over a 3-year time horizon. The analysis was carried out from the perspective of a hospital with a protocol-driven strategy for BLC adoption.","length":584,"tagName":"p"},{"type":"text","content":"Results: In Denmark, with a differential tariff system between BLC and white light cystoscopy (WLC), the additional cost of the technology was fully offset by the tariff, with a net surplus of €170 per patient. In France and Italy, both of which have a flat-rate tariff for BLC and WLC, there was a net cost of €108 and €120 per patient respectively. In Finland, with a block contract system, the net cost per patient was €206.","length":427,"tagName":"p"},{"type":"text","content":"Conclusions: Diagnostic technologies like BLC often present unique challenges for economic evaluation, requiring linkage between improved detection and downstream clinical and economic outcomes. In this study, incorporating predicted clinical outcomes and subsequently modelling the costs based on risk stratification, guideline recommendations and funding mechanisms, provides a useful tool to predicting overall cost for patient populations pe...

More updates from Photocure Asa